Using patient pancreatic cancer organoids with natural KRAS G12V mutation and HLA-A*11:01 expression, our identified HLA-A*11:01–restricted KRAS G12V–reactive TCR demonstrated the ability to specifically recognize all tested patient cancer organoids to different degrees, but only kill some of them, which indicates that individual patients likely will respond differently to therapy with TCR-transduced T cells, potentially due to different levels of antigen presentation in tumor cells. Here, KRAS is linked to neoplasm.